Nasdaq · CIK 0001326110
IBRX ImmunityBio, Inc.
Insider trading from SEC Form 4. Last filing 7 d ago. Close $10.51 on Oct 9, 2026, +431% from the 52-week low and -9% from the high.
ImmunityBio, Inc. (IBRX) has 41 SEC Form 4 filings on file from 9 insiders, the latest filed on Oct 6, 2026. In the last 90 days insiders made 0 open-market buys worth $0 and 2 open-market sells worth $1.1M, net -$1.1M.
7 open-market trades have been scored at IBRX. The newest: Cheryl Cohen (director) sold $851k of stock on Oct 2, 2026, filed Oct 6, 2026, scored 21 (weak), under a 10b5-1 plan. The largest of the 7 shown: Barry J. Simon (director) sold $1.8M on Feb 20, 2026, scored 13 (weak), under a 10b5-1 plan. 2 insiders sold within 14 days of each other around Oct 2, 2026.
IBRX closed at $10.51 on Oct 9, 2026, 431% above its 52-week low and 9% below its 52-week high.
Last 90 days
Price and insider trades, last year
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at ImmunityBio, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 21Weak | Cheryl Cohen director sell | $851k 81,056 shares | -45% | - | |
| 16Weak | Barry J. Simon director sell | $269k 25,000 shares | -1% | - | |
| 27Weak | Barry J. Simon director sell | $901k 75,000 shares | -3% | +511% from low0% from high | |
| 13Weak | Barry J. Simon director sell | $1.8M 175,000 shares | -6% | +360% from low0% from high | |
| 21Weak | Christobel Selecky director sell | $250k 25,000 shares | -100% | +420% from low0% from high | |
| 28Weak | Barry J. Simon director sell | $1.1M 151,967 shares | -5% | +243% from low0% from high | |
| 25Weak | Christobel Selecky director sell | $438k 75,000 shares | -150% | +192% from low0% from high |
Transactions
The newest 50 of 102 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Oct 2, 2026 | Cheryl Cohen director | MOption exercise Common Stock10b5-1 | +55,979 | $2.98 | $167k | 181,365 | 7 d ago |
| Oct 5, 2026 | Barry J. Simon director | SOpen-market sale Common Stock10b5-1 | -25,000 | $10.75 | $269k | 2,777,788 | 7 d ago |
| Oct 2, 2026 | Cheryl Cohen director | SOpen-market sale Common Stock10b5-1 | -81,056 | $10.50 | $851k | 100,309 | 7 d ago |
| Oct 2, 2026 | Cheryl Cohen director | MOption exercise Stock Option (right to buy)derivative10b5-1 | -55,979 | $0.00 | $0 | 55,979 | 7 d ago |
| Jun 9, 2026 | Cheryl Cohen director | AGrant or award Stock Option (right to buy)derivative | +65,600 | $0.00 | $0 | 65,600 | Jun 10, 2026 |
| Jun 9, 2026 | Wesley Clark director | AGrant or award Stock Option (right to buy)derivative | +65,600 | $0.00 | $0 | 65,600 | Jun 10, 2026 |
| Jun 9, 2026 | Michael D Blaszyk director | AGrant or award Stock Option (right to buy)derivative | +65,600 | $0.00 | $0 | 65,600 | Jun 10, 2026 |
| Mar 31, 2026 | Patrick Soon-Shiong See remarks | CConversion Common Stockindirect: See footnote | +4,606,596 | $5.43 | $25M | 251,018,873 | Apr 2, 2026 |
| Mar 31, 2026 | Patrick Soon-Shiong See remarks | CConversion Second Amended and Restated Convertible Promissory Notederivativeindirect: See footnote | - | $0.00 | - | - | Apr 2, 2026 |
| Feb 24, 2026 | Barry J. Simon director | SOpen-market sale Common Stock10b5-1 | -75,000 | $12.01 | $901k | 2,850,821 | Feb 26, 2026 |
| Feb 23, 2026 | Christobel Selecky director | MOption exercise Common Stock10b5-1 | +25,000 | $2.98 | $75k | 25,000 | Feb 24, 2026 |
| Feb 22, 2026 | Patrick Soon-Shiong See remarks | MOption exercise Common Stock | +114,329 | $0.00 | $0 | 29,816,081 | Feb 24, 2026 |
| Feb 22, 2026 | Regan J Lauer Chief Accounting Officer | MOption exercise Common Stock | +4,065 | $0.00 | $0 | 117,548 | Feb 24, 2026 |
| Feb 22, 2026 | David C. Sachs Chief Financial Officer | MOption exercise Common Stock | +40,650 | $0.00 | $0 | 320,825 | Feb 24, 2026 |
| Feb 20, 2026 | Barry J. Simon director | SOpen-market sale Common Stock10b5-1 | -10,000 | $9.25 | $93k | 3,081,604 | Feb 24, 2026 |
| Feb 22, 2026 | Richard Adcock CEO & President | MOption exercise Common Stock | +152,439 | $0.00 | $0 | 637,904 | Feb 24, 2026 |
| Feb 22, 2026 | Richard Adcock CEO & President | FTax withholding Common Stock | -77,560 | $8.70 | $675k | 560,344 | Feb 24, 2026 |
| Feb 22, 2026 | Patrick Soon-Shiong See remarks | FTax withholding Common Stock | -58,170 | $8.70 | $506k | 29,757,911 | Feb 24, 2026 |
| Feb 22, 2026 | Regan J Lauer Chief Accounting Officer | FTax withholding Common Stock | -1,673 | $8.70 | $15k | 115,875 | Feb 24, 2026 |
| Feb 22, 2026 | Barry J. Simon director | MOption exercise Common Stock10b5-1 | +15,243 | $0.00 | $0 | 3,096,847 | Feb 24, 2026 |
| Feb 23, 2026 | Christobel Selecky director | SOpen-market sale Common Stock10b5-1 | -25,000 | $10.00 | $250k | 0 | Feb 24, 2026 |
| Feb 22, 2026 | David C. Sachs Chief Financial Officer | FTax withholding Common Stock | -20,682 | $8.70 | $180k | 300,143 | Feb 24, 2026 |
| Feb 22, 2026 | Richard Adcock CEO & President | MOption exercise Restricted Stock Unitsderivative | -152,439 | $0.00 | $0 | 152,439 | Feb 24, 2026 |
| Feb 22, 2026 | Regan J Lauer Chief Accounting Officer | MOption exercise Restricted Stock Unitsderivative | -4,065 | $0.00 | $0 | 4,065 | Feb 24, 2026 |
| Feb 22, 2026 | Barry J. Simon director | FTax withholding Common Stock10b5-1 | -6,026 | $8.70 | $52k | 3,090,821 | Feb 24, 2026 |
| Feb 23, 2026 | Christobel Selecky director | MOption exercise Stock Option (right to buy)derivative10b5-1 | -25,000 | $0.00 | $0 | 67,937 | Feb 24, 2026 |
| Feb 22, 2026 | David C. Sachs Chief Financial Officer | MOption exercise Restricted Stock Unitsderivative | -40,650 | $0.00 | $0 | 40,651 | Feb 24, 2026 |
| Feb 23, 2026 | Barry J. Simon director | SOpen-market sale Common Stock10b5-1 | -165,000 | $10.25 | $1.7M | 2,925,821 | Feb 24, 2026 |
| Feb 22, 2026 | Barry J. Simon director | MOption exercise Restricted Stock Unitsderivative10b5-1 | -15,243 | $0.00 | $0 | 15,245 | Feb 24, 2026 |
| Feb 22, 2026 | Patrick Soon-Shiong See remarks | MOption exercise Restricted Stock Unitsderivative | -114,329 | $0.00 | $0 | 114,329 | Feb 24, 2026 |
| Feb 10, 2026 | Patrick Soon-Shiong See remarks | MOption exercise Common Stock | +274,122 | $0.00 | $0 | 29,820,312 | Feb 12, 2026 |
| Feb 10, 2026 | Regan J Lauer Chief Accounting Officer | MOption exercise Common Stock | +5,482 | $0.00 | $0 | 115,740 | Feb 12, 2026 |
| Feb 10, 2026 | David C. Sachs Chief Financial Officer | MOption exercise Common Stock | +82,236 | $0.00 | $0 | 322,818 | Feb 12, 2026 |
| Feb 10, 2026 | Richard Adcock CEO & President | MOption exercise Common Stock | +274,122 | $0.00 | $0 | 625,513 | Feb 12, 2026 |
| Feb 10, 2026 | Richard Adcock CEO & President | FTax withholding Common Stock | -140,048 | $6.93 | $971k | 485,465 | Feb 12, 2026 |
| Feb 10, 2026 | Patrick Soon-Shiong See remarks | FTax withholding Common Stock | -118,560 | $6.93 | $822k | 29,701,752 | Feb 12, 2026 |
| Feb 10, 2026 | Regan J Lauer Chief Accounting Officer | FTax withholding Common Stock | -2,257 | $6.93 | $16k | 113,483 | Feb 12, 2026 |
| Feb 10, 2026 | David C. Sachs Chief Financial Officer | FTax withholding Common Stock | -42,643 | $6.93 | $296k | 280,175 | Feb 12, 2026 |
| Feb 10, 2026 | Richard Adcock CEO & President | MOption exercise Restricted Stock Unitsderivative | -274,122 | $0.00 | $0 | 548,246 | Feb 12, 2026 |
| Feb 10, 2026 | Regan J Lauer Chief Accounting Officer | MOption exercise Restricted Stock Unitsderivative | -5,482 | $0.00 | $0 | 10,965 | Feb 12, 2026 |
| Feb 10, 2026 | David C. Sachs Chief Financial Officer | MOption exercise Restricted Stock Unitsderivative | -82,236 | $0.00 | $0 | 164,474 | Feb 12, 2026 |
| Feb 10, 2026 | Patrick Soon-Shiong See remarks | MOption exercise Restricted Stock Unitsderivative | -274,122 | $0.00 | $0 | 548,246 | Feb 12, 2026 |
| Jan 20, 2026 | Barry J. Simon director | SOpen-market sale Common Stock10b5-1 | -76,967 | $6.54 | $503k | 3,166,604 | Jan 21, 2026 |
| Jan 16, 2026 | Christobel Selecky director | MOption exercise Common Stock10b5-1 | +50,000 | $2.98 | $149k | 50,000 | Jan 21, 2026 |
| Jan 20, 2026 | Barry J. Simon director | SOpen-market sale Common Stock10b5-1 | -75,000 | $7.88 | $591k | 3,091,604 | Jan 21, 2026 |
| Jan 16, 2026 | Christobel Selecky director | SOpen-market sale Common Stock10b5-1 | -50,000 | $5.00 | $250k | 0 | Jan 21, 2026 |
| Jan 20, 2026 | Christobel Selecky director | MOption exercise Common Stock10b5-1 | +25,000 | $2.98 | $75k | 25,000 | Jan 21, 2026 |
| Jan 20, 2026 | Christobel Selecky director | SOpen-market sale Common Stock10b5-1 | -25,000 | $7.51 | $188k | 0 | Jan 21, 2026 |
| Jan 16, 2026 | Christobel Selecky director | MOption exercise Stock Option (right to buy)derivative10b5-1 | -50,000 | $0.00 | $0 | 117,937 | Jan 21, 2026 |
| Jan 20, 2026 | Christobel Selecky director | MOption exercise Stock Option (right to buy)derivative10b5-1 | -25,000 | $0.00 | $0 | 92,937 | Jan 21, 2026 |
Insiders
Everyone who has filed a Form 4 here.
- Richard AdcockCEO & President
- Michael D Blaszykdirector
- Wesley Clarkdirector
- Cheryl Cohendirector
- Regan J LauerChief Accounting Officer
- Patrick Soon-ShiongSee remarks
- David C. SachsChief Financial Officer
- Christobel Seleckydirector
- Barry J. Simondirector
Questions about IBRX
Answered from the filings on this page, as of the latest one.
Are insiders buying IBRX?
As of Oct 6, 2026, SEC Form 4 filings show 0 open-market buys worth $0 by 0 insiders and 2 open-market sells worth $1.1M by 2 insiders at ImmunityBio, Inc. in the last 90 days, net -$1.1M. Only purchases (code P) and sales (code S) count; grants, option exercises and tax withholding do not.
Who was the last insider to trade IBRX on the open market?
Cheryl Cohen (director) sold $851k of IBRX on Oct 2, 2026 and filed the Form 4 on Oct 6, 2026. InsiderTell scored 21 (weak), under a 10b5-1 plan, with 2 insiders on the same side within 14 days.
How many insiders file Form 4 at ImmunityBio, Inc.?
9 people have filed a Form 4 at ImmunityBio, Inc., among them Richard Adcock (CEO & President), Michael D Blaszyk (director), Wesley Clark (director). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.